|Day Low/High||66.20 / 66.98|
|52 Wk Low/High||60.32 / 79.61|
Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...
Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...
The RMPIA rose 10.5% during the first half of the current quarter.
I still believe it will be a big year for buyouts across the biotech industry.
It's behavioral finance at its finest, and makes for a fascinating debate.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
And why maintaining a small position in defense stocks is important.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Gilead has been trying to turn things around but few see that turn coming anytime soon.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
It becomes difficult for me to tell you where to run in these markets...
Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
This biotech's weekly chart is very encouraging.
Taking the measure of what's keeping the markets in the dumps.
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...